Market intelligence workspace
Market intelligence workspace
Reported EPS compared with analyst estimates.
Core valuation, range, and trading metrics.
Free market coverage from the current news feed.
EyePoint, Inc. granted non-statutory stock options to three new employees as inducement awards on June 15, 2026. The company granted options to purchase 39,700 shares at an exercise price of $12.08 per share with a ten-year term and four-year vesting schedule. The grants were approved by the Compensation Committee in accordance with NASDAQ regulations.
Read storyEyePoint, Inc. (EYPT) announced participation in three upcoming healthcare conferences in May-June 2026. The company also reported a third consecutive positive Data Safety Monitoring Committee (DSMC) recommendation for its Phase 3 wet AMD trials of DURAVYU™, with topline data expected in mid-2026. The trials continue to show a favorable safety profile.
Read storyEyePoint announced Q1 2026 financial results with $223 million in cash runway extending into Q4 2027. The company's lead product DURAVYU is progressing through Phase 3 trials for wet AMD and DME, with topline data expected beginning mid-2026 for wet AMD and Q4 2027 for DME. However, net revenue declined significantly to $0.7 million from $24.5 million year-over-year, while operating expenses increased to $87.9 million, resulting in a net loss of $84.8 million.
Read storyCormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.
Read storyEyePoint, Inc. (Nasdaq: EYPT) granted non-statutory stock options to purchase 20,000 shares of common stock to six new employees as inducement awards on March 13, 2026, with an exercise price of $13.20 per share. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with topline data expected beginning in mid-2026 for wet AMD.
Read storyParkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.
Read storyThe strongest signal is the sharp drop in the stock, with EYPT down 14.7% on the day and down over the week while the recent options flow shows fairly even spending between calls and puts. The wider picture looks mixed: analyst coverage leans positive, a recent insider buy stands out, but recent filings also include insider and institutional selling, and the next earnings date is still ahead.
Generated Aug 21, 2026EyePoint, Inc. Common Stock
Updated Aug 21, 5:55 AM UTCRecent disclosed activity connected to public officials.
Premium crowd and conversation intelligence.
Notable contracts and premium concentration.
Large institutional position updates.